We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+16.12%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.94B
AUM Growth
+$295M
Cap. Flow
+$29.2M
Cap. Flow %
0.74%
Top 10 Hldgs %
26.69%
Holding
163
New
20
Increased
50
Reduced
30
Closed
15

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$44.7M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$22.4M
3
INZY
Inozyme Pharma
INZY
+$21.9M
4
KYMR icon
Kymera Therapeutics
KYMR
+$21.7M
5
HUM icon
Humana
HUM
+$20.7M

Top Sells

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$41.5M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$32M
3
CI icon
Cigna
CI
+$30.2M
4
AMGN icon
Amgen
AMGN
+$29.7M
5
ALLO icon
Allogene Therapeutics
ALLO
+$18.9M

Sector Composition

Rank Sector Weight
1 Healthcare 90.05%
2 Consumer Staples 1.43%
3 Consumer Discretionary 0.93%
4 Industrials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHR icon
51
Phreesia
PHR
$769M
$25.7M 0.65%
800,000
+148,500
+23% +$4.42M
MIRM icon
52
Mirum Pharmaceuticals
MIRM
$6.02B
$25.6M 0.65%
1,327,614
+7,704
+0.6% +$165K
BFAM icon
53
Bright Horizons
BFAM
$3.81B
$25.2M 0.64%
165,500
+67,000
+68% +$8.43M
LKFT
54
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.76B
$24.8M 0.63%
175,000
– –
COLL icon
55
Collegium Pharmaceutical
COLL
$882M
$24.5M 0.62%
1,175,000
– –
ASMB icon
56
Assembly Biosciences
ASMB
$530M
$24.1M 0.61%
121,993
-2,917
-2% -$735K
INZY
57
DELISTED
Inozyme Pharma
INZY
$23.1M 0.59%
+879,954
New +$21.9M
KYMR icon
58
Kymera Therapeutics
KYMR
$9.03B
$22.9M 0.58%
+709,965
New +$21.7M
ACHC icon
59
Acadia Healthcare
ACHC
$2.96B
$22.4M 0.57%
760,000
-140,000
-16% -$4.06M
GH icon
60
Guardant Health
GH
$22.4B
$21.2M 0.54%
190,000
– –
MNTA
61
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$21M 0.53%
400,000
– –
APLT
62
DELISTED
Applied Therapeutics
APLT
$20.6M 0.52%
991,573
– –
RPRX icon
63
Royalty Pharma
RPRX
$25.8B
$20.4M 0.52%
485,000
-15,000
-3% -$644K
LONA
64
LeonaBio Inc
LONA
$70.5M
$20.4M 0.52%
+110,270
New +$18.4M
ALLK
65
DELISTED
Allakos
ALLK
$19.7M 0.5%
241,582
+2,550
+1% +$207K
NVCR icon
66
NovoCure
NVCR
$2.02B
$19.5M 0.49%
175,000
– –
PPD
67
DELISTED
PPD, Inc. Common Stock
PPD
$19.4M 0.49%
525,000
+37,500
+8% +$1.19M
TVTX icon
68
Travere Therapeutics
TVTX
$5.74B
$18.9M 0.48%
1,024,261
– –
KRTX
69
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$18.9M 0.48%
244,106
+40,794
+20% +$3.48M
HQY icon
70
HealthEquity
HQY
$8.93B
$18.5M 0.47%
360,100
+40,000
+12% +$2.2M
CGEN icon
71
Compugen
CGEN
$221M
$18.4M 0.47%
1,132,775
+2,400
+0.2% +$39.3K
AMRN
72
Amarin Corp
AMRN
$298M
$18.3M 0.46%
217,500
-15,000
-6% -$1.8M
TGTX icon
73
TG Therapeutics
TGTX
$7.52B
$18.3M 0.46%
682,926
– –
RLAY icon
74
Relay Therapeutics
RLAY
$4.37B
$17.6M 0.45%
+413,674
New +$15.8M
SWAV
75
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$16.7M 0.42%
220,000
+22,500
+11% +$1.28M
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Rock Springs Capital Management held 163 positions worth $3.94B, up 8.1% from $3.65B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management's Q3 2020 filing shows 20 new, 50 increased, 30 reduced and 15 closed positions. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 650,000 shares worth $50.5M. The largest sale was Portola Pharmaceuticals, Inc., an estimated $41.5M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 92% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q3 2020 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 650,000 shares worth $50.5M.
  • Rock Springs Capital Management added most to Acadia Pharmaceuticals in Q3 2020, an estimated $22.4M increase.
  • Rock Springs Capital Management's biggest Q3 2020 reduction was Vertex Pharmaceuticals, cutting an estimated $32M.
  • Rock Springs Capital Management fully exited Portola Pharmaceuticals, Inc. in Q3 2020, selling an estimated $41.5M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $3.94B portfolio in Q3 2020.
  • Rock Springs Capital Management opened 20 new positions and closed 15 in Q3 2020.
  • Rock Springs Capital Management's portfolio value rose 8.1% quarter-over-quarter to $3.94B.

Based on Rock Springs Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.